Natera, Inc. (NTRA) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Natera, Inc. is a diagnostics company utilizing cell-free DNA (cfDNA) technology across three primary healthcare sectors: oncology, women's health, and organ health. Key products include Signatera (oncology), Panorama (prenatal), and Horizon (carrier screening). The company operates as a single reporting segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $696,644 | $501,830 |
| Gross Margin | $450,833 (64.7%) | $316,765 (63.1%) |
| Net Loss | $(85,091) | $(66,936) |
| Operating Cash Flow | $40,171 | $44,452 |
| Cash & Equivalents | $1,087,932 | $973,768 |
| Debt (Credit Line) | $80,305 | $80,323 |
Additional Metrics: Stock-based compensation expense was $95.1 million. The company processed approximately 1.01 million tests in Q1 2026 compared to 855,100 in Q1 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 38.8% year-over-year, driven by a 38.8% increase in product revenues ($693.9M vs. $500.0M). This growth was attributed to increased test volumes and average selling price improvements.
- Expense Increases:
- R&D Expenses: Increased 63.2% to $210.7M, primarily due to higher headcount, lab/clinical trial costs, and stock-based compensation.
- SG&A Expenses: Increased 22.9% to $327.9M, driven by salary increases, marketing, and legal costs.
- Amortization: New amortization of acquired intangible assets of $5.7M appeared due to the Foresight Diagnostics acquisition.
- Net Loss Expansion: Net loss widened by 27.1% to $85.1M, reflecting the significant investment in R&D and SG&A outpacing revenue growth.
- Acquisition Impact: The December 2025 acquisition of Foresight Diagnostics contributed to goodwill ($140.9M) and intangible assets ($367.4M), with contingent consideration liabilities totaling $125.6M.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management expects to continue incurring net losses as they invest in R&D and commercialization. They believe existing cash resources ($1.1B) are sufficient to meet requirements for at least 12 months. The company is focused on expanding reimbursement for microdeletions screening (Panorama) and growing Signatera adoption.
Risks and Contingencies:
- Legal Proceedings: Significant ongoing litigation includes patent disputes with CareDx, ArcherDX, and Guardant Health. A jury verdict against Natera in the Guardant false advertising case resulted in $292.5M in damages (pending appeal). Natera also faces a $57.0M jury verdict from Ravgen (pending appeal) and has accrued approximately $33.0M for probable legal contingencies.
- Reimbursement: Revenue growth depends heavily on third-party payer reimbursement rates and coverage determinations, particularly for Panorama microdeletions.
- Contingent Consideration: Up to $175.0M in additional payments may be required to Foresight Diagnostics shareholders based on milestone achievements through 2027.
Investor Verification Checklist
- Legal Exposure: Verify the status of the $292.5M Guardant verdict and the $57.0M Ravgen verdict, including the likelihood of successful appeals.
- Reimbursement Trends: Monitor updates on third-party payer coverage for Panorama microdeletions and Signatera, as these drive revenue stability.
- Contingent Liabilities: Track the probability of achieving the milestones triggering the remaining $175M Foresight Diagnostics contingent consideration.
- Cash Burn vs. Runway: Assess the sustainability of the current operating cash flow ($40.2M) against the accelerating R&D and SG&A spend.
- Acquisition Integration: Evaluate the integration progress of Foresight Diagnostics and the realization of projected synergies.